|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,766.00 GBX | +0.13% |
|
+1.47% | -0.17% |
| 07:21pm | ASTRAZENECA : Jefferies remains its Buy rating | ZD |
| 05:42pm | AstraZeneca, Owkin to Develop AI Agents for Drug Discovery Decision-making | MT |
MarketScreener Strategies
Search
 | AstraZeneca: Desirable start to 2026, but most strengths are already priced in | April 29, 2026 at 06:48 pm IST |
| AstraZeneca: Strengths remain aptly valued | March 06, 2026 at 11:28 pm IST |
 | AstraZeneca: Bright 2026 outlook a key takeaway | February 10, 2026 at 10:31 pm IST |
| AstraZeneca benefits from oncology momentum but valuation limits upside | November 19, 2025 at 06:13 pm IST |
| AstraZeneca delivers Q3 earnings beat but upside looks limited | November 06, 2025 at 08:44 pm IST |
 | AstraZeneca's CEO reportedly considers listing in the United States | July 02, 2025 at 01:09 pm IST |
No results for this search
Filters
Headlines
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- MarketScreener Strategies
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition